文献速递糖尿病

使用第二代基础胰岛素治疗的2型糖尿病合并慢性肾脏病新用户中的血糖控制、低血糖风险与全因死亡率:一项全国注册队列研究

Glycaemic control, risk of hypoglycaemia and all-cause mortality in new users of second-generation basal insulin with type 2 diabetes and chronic kidney disease: a nationwide register-based cohort study.
PubMed 文献 · Diabetologia · 2023-07-28

基于丹麦全国糖尿病注册数据,纳入6519例合并中至终末期慢性肾脏病的2型糖尿病新用户(德谷胰岛素100 U/ml组3747例,甘精胰岛素300 U/ml组2772例)。两组HbA1c降幅、低血糖住院率(率比1.02,95%CI 0.70-1.49)及全因死亡率(率比0.98,95%CI 0.84-1.15)均无显著差异。

要点

  • 德谷胰岛素100 U/ml与甘精胰岛素300 U/ml在合并中至终末期慢性肾脏病的2型糖尿病患者中HbA1c降幅无显著差异。
  • 低血糖住院率(率比1.02,95%CI 0.70-1.49)与全因死亡率(率比0.98,95%CI 0.84-1.15)在两组间相似。
  • 作者认为两种治疗方案在这一脆弱人群中同样有效且安全。

核心结论

  • 在合并中至终末期慢性肾脏病的2型糖尿病新用户真实世界人群中,甘精胰岛素300 U/ml与德谷胰岛素100 U/ml在HbA1c降幅、低血糖住院率或全因死亡率方面无差异。
  • 作者据此认为两种治疗方案在这一脆弱人群中同样有效且安全。

研究设计与样本

  • 基于丹麦全国糖尿病注册数据的注册队列研究,纳入6519例合并中至终末期慢性肾脏病的2型糖尿病新用户。
  • 德谷胰岛素100 U/ml组3747例,甘精胰岛素300 U/ml组2772例,女性占44%。
  • 德谷胰岛素100 U/ml起始于2013年,甘精胰岛素300 U/ml起始于2015年,随访至2020年。
  • HbA1c轨迹采用混合效应模型建模,低血糖住院率与全因死亡率分别采用泊松似然模型建模。

主要发现

  • 甘精胰岛素300 U/ml组平均(SD)2型糖尿病病程14.4(6.6)年 vs 德谷胰岛素100 U/ml组15.2(6.7)年,甘精胰岛素300 U/ml组显著更短。
  • 甘精胰岛素300 U/ml组中位(IQR)慢性肾脏病病程2.3(1.3,3.9)年 vs 德谷胰岛素100 U/ml组2.8(1.6,4.6)年,甘精胰岛素300 U/ml组显著更短。
  • 中位(IQR)随访时间:甘精胰岛素300 U/ml组1.0(0.5-1.6)年,德谷胰岛素100 U/ml组1.0(0.3-1.5)年,两组相似。
  • 两组平均HbA1c从起始至随访结束均降低13-14 mmol/mol(1.2-1.3%),其中第一年降幅最大(8-9 mmol/mol [0.7-0.8%]),两组HbA1c降幅无显著差异。
  • 低血糖住院率(率比1.02 [95%CI 0.70, 1.49],德谷胰岛素100 U/ml vs 甘精胰岛素300 U/ml)与全因死亡率(率比0.98 [95%CI 0.84, 1.15],德谷胰岛素100 U/ml vs 甘精胰岛素300 U/ml)在两组间相似。

临床怎么用

  • 在合并中至终末期慢性肾脏病的2型糖尿病新用户中,德谷胰岛素100 U/ml与甘精胰岛素300 U/ml在HbA1c降幅、低血糖住院率和全因死亡率方面无差异。
  • 作者认为这两种治疗方案在这一脆弱人群中同样有效且安全。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this study was to compare the performance of the second-generation basal insulins, insulin degludec 100 U/ml (Deg-100) and insulin glargine 300 U/ml (Gla-300), in terms of change in HbA1c, hospitalisation for hypoglycaemia and all-cause mortality among individuals with type 2 diabetes and concurrent chronic kidney disease. METHODS: This register-based cohort study, based on the entire Danish diabetes population, included 6519 new users of Deg-100 and Gla-300 with type 2 diabetes and moderate to end-stage chronic kidney disease. HbA1c trajectories, from initiation of either Deg-100 (2013) or Gla-300 (2015) to end of follow-up (2020), were modelled with mixed-effect models while rates of hospitalisation for hypoglycaemia and all-cause mortality were modelled in separate models using Poisson likelihood. RESULTS: Of the 6519 (44% women) individuals included in the study, 3747 were exposed to Deg-100 and 2772 to Gla-300. Both mean (SD) type 2 diabetes duration (14.4 [6.6] years vs 15.2 [6.7] years) and median (IQR) chronic kidney disease duration (2.3 [1.3, 3.9] years vs 2.8 [1.6, 4.6] years) were significantly shorter in the Gla-300 group. The median (IQR) follow-up time was similar between groups: 1.0 (0.5-1.6) year for Gla-300 and 1.0 (0.3-1.5) year for Deg-100. In both groups mean HbA1c levels were reduced by 13-14 mmol/mol (1.2-1.3%) from initiation to end of follow-up, with the largest reduction (of 8-9 mmol/mol [0.7-0.8%]) occurring during the first year. There was no significant difference in HbA1c reduction between Deg-100 and Gla-300. Both the rate of hospitalisation for hypoglycaemia (rate ratio 1.02 [95% CI 0.70, 1.49], Deg-100 vs Gla-300) and the rate of all-cause mortality (rate ratio 0.98 [95% CI 0.84, 1.15], Deg-100 vs Gla-300) were similar between the groups. CONCLUSIONS/INTERPRETATION: We found no difference in HbA1c reduction, hospitalisation for hypoglycaemia or all-cause mortality between Gla-300 and Deg-100 in a real-world population of new users with type 2 diabetes and moderate to end-stage chronic kidney disease. Therefore, we conclude that these two treatment options are equally effective and safe in this vulnerable population.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Kosjerina V, Carstensen B, Amadid H, et al. Glycaemic control, risk of hypoglycaemia and all-cause mortality in new users of second-generation basal insulin with type 2 diabetes and chronic kidney disease: a nationwide register-based cohort study. Diabetologia. 2023. PMID: 37505281. doi:10.1007/s00125-023-05971-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。